Arteriocyte is now a part of Isto Biologics.

News + Views


ISTO Technologies Announces Release of Peer-Reviewed Scientific Publication Related to Its Cartilage Technology

May 12, 2010

ST. LOUIS, MO — (Marketwire – May 12, 2010) – ISTO Technologies, Inc. announced today the publication of a scientific paper in The American Journal of Sports Medicine (AJSM). The manuscript, titled “The Potential of Human Allogeneic Juvenile Chondrocytes for Restoration of Articular Cartilage” by H. Davis Adkisson et al., is currently available on-line at as an AJSM PreView article and will be included in the July 2010 edition of the leading peer-reviewed orthopaedic and sports medicine journal. The scientific piece describes the superior ability of chondrocytes derived from juvenile articular cartilage to rapidly grow and produce significantly greater levels of cartilage macromolecules than cells derived from adult cartilage.

In the article, ISTO Technologies and its collaborators, James A. Martin, Ph.D. and Joseph A. Buckwalter, M.D. from the University of Iowa, show an age related deterioration in the ability of human chondrocytes to proliferate and produce new matrix. “Our research shows that juvenile chondrocytes possess greater and more predictable chondrogenic activity than adult chondrocytes; this difference may be a key factor for achieving successful repair in adult cartilage, which normally displays poor regenerative potential,” said Dr. Buckwalter, Professor and Chairman of Orthopaedics and Rehabilitation at the University of Iowa.
In conjunction with its cartilage research, ISTO has developed a proprietary cell-expansion process for growing juvenile chondrocytes that may address the serious unmet medical need for restoration of cartilage defects arising from acute traumatic injury or degeneration. Cartilage acts as a “shock absorber” in all joints, including the spinal disc. Osteoarthritis and degenerative disc disease are two examples of disorders associated with cartilage destruction. “Our scalable technology for growing juvenile chondrocytes offers a platform that potentially addresses medical needs in a number of clinical applications,” said Mitchell Seyedin, Ph.D., President & CEO of ISTO Technologies.

The Company’s cartilage regeneration programs currently in human trials include: DeNovo® ET, a scaffold-free tissue engineered graft displaying hyaline characteristics manufactured for the repair of cartilage defects in the knee; and NuQu™, an injectable formulation of chondrocytes for early intervention and restoration of disc function for patients suffering from discogenic back pain.

About ISTO
ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sports medicine applications. ISTO’s products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at or contact Scott Gill, Chief Financial Officer, at 314-995-6049.

To top